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Abstract
Purpose Endothelial dysfunction is central to the pathogenesis of acute coronary syndrome. The study of diseased endothelium is
very challenging due to inherent difficulties in isolating endothelial cells from the coronary vascular bed.We sought to isolate and
characterise coronary endothelial cells from patients undergoing thrombectomy for myocardial infarction to develop a patient-
specific in vitro model of endothelial dysfunction.
Methods In a prospective cohort study, 49 patients underwent percutaneous coronary intervention with thrombus aspiration.
Specimens were cultured, and coronary endothelial outgrowth (CEO) cells were isolated. CEO cells, endothelial cells isolated
from peripheral blood, explanted coronary arteries, and umbilical veins were phenotyped and assessed functionally in vitro and
in vivo.
Results CEO cells were obtained from 27/37 (73%) atherothrombotic specimens and gave rise to cells with cobblestone mor-
phology expressing CD146 (94 ± 6%), CD31 (87 ± 14%), and vonWillebrand factor (100 ± 1%). Proliferation of CEO cells was
impaired compared to both coronary artery and umbilical vein endothelial cells (population doubling time, 2.5 ± 1.0 versus 1.6 ±
0.3 and 1.2 ± 0.3 days, respectively). Cell migration was also reduced compared to umbilical vein endothelial cells (29 ± 20%
versus 85±19%). Importantly, unlike control endothelial cells, dysfunctional CEO cells did not incorporate into new vessels or
promote angiogenesis in vivo.
Conclusions CEO cells can be reliably isolated and cultured from thrombectomy specimens in patients with acute coronary
syndrome. Compared to controls, patient-derived coronary endothelial cells had impaired capacity to proliferate, migrate, and
contribute to angiogenesis. CEO cells could be used to identify novel therapeutic targets to enhance endothelial function and
prevent acute coronary syndromes.
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Introduction
Atherothrombosis is characterised by atherosclerotic plaque
rupture with thrombus formation and is the major cause of
acute coronary syndromes and cardiovascular death.
Disruption of the endothelial cell monolayer has been impli-
cated in the onset [1], progression [2], and clinical manifesta-
tions [3] of atherothrombosis. This monolayer acts as a non-
adhesive surface for platelets and leucocytes and produces
important factors in the regulation of inflammation, thrombo-
sis, and blood flow [4]. It is now widely recognised that a
variety of cardiovascular risk factors including cigarette
smoking and hypercholesterolemia cause endothelial dysfunc-
tion [5].
Our understanding of the cellular mechanisms of endothelial
dysfunction in coronary heart disease has been hampered by
our inability to isolate and study endothelial cells from the
coronary circulation. Most of our observations have been based
on an assessment of blood flow in the forearm [6, 7] or from
measurement of surrogate biomarkers in plasma, such as von
Willebrand factor (vWF) and soluble thrombomodulin [8].
Whilst the number of circulating endothelial cells can be quan-
tified in blood [9, 10] and novel methods have been developed
to isolate endothelial cells from superficial veins and arteries
[11], our understanding of the cellular mechanisms of endothe-
lial dysfunction in acute coronary syndrome is largely inferred
from the study of endothelial cells from more readily available
vascular beds. The study of late endothelial outgrowth cells
(EOCs) from peripheral blood [12, 13] whose origin is contro-
versial [14], or commercially acquired coronary artery endothe-
lial cells from vascular beds of unknown health, or umbilical
vein endothelial cells [15] from vessels that do not develop
atherosclerosis, provides important but limited insights into
the pathogenesis of coronary artery disease [16, 17].
We therefore sought to isolate and characterise coronary
endothelial cells directly from thrombectomy specimens in
patients undergoing treatment for acute myocardial infarction
in order to generate a patient-specific in vitro model of endo-
thelial dysfunction in coronary heart disease.We hypothesised
that coronary endothelial cells would have impaired function
compared to endothelial cells derived from other vascular
beds.
Methods
An expanded Methods section is available in the Online Data
Supplement
Study Population
Coronary atherothrombotic specimens (n = 49) were obtained
from patients receiving percutaneous coronary intervention
(PCI) with thrombectomy for the treatment of acute ST-
segment elevation myocardial infarction (STEMI). Venous
blood (n = 3) was obtained from patients with prior myocar-
dial infarction. The study protocol was granted by the East of
Scotland Research Ethics Service REC1 (15/ES/0094). The
project was also approved by the South East Scotland
BioResource Scientific Review Committee (SR019). All sam-
ples were collected with written informed consent of the
participants.
Patient and Public Involvement statement:
Patients and the public were not involved in the design,
reporting, or dissemination of the findings from this study.
Cell Isolation
Specimens were washed with phosphate buffered saline
(PBS) and manually disaggregated. Tissue explants were
seeded into collagen-I coated 6-well plates and maintained
under standard cell culture conditions. After 24 h, tissue ex-
plants, non-adherent cells, and debris were aspirated. Medium
was changed every other day until the first passage of coro-
nary endothelial outgrowth (CEO) cells. Late EOCs were de-
rived by seeding the mononuclear cell fraction of peripheral
blood onto collagen-I coated 6-well plates as previously de-
scribed [12, 13]. Human coronary artery endothelial cells
(HCAECs) and human umbilical vein endothelial cells
(HUVECs) were obtained commercially from single and/or
pooled donors. All cultured endothelial cells were maintained
under identical conditions.
Cellular Characterisation of Atherothrombotic
Specimens
Atherothrombotic specimens were formalin-fixed and paraf-
fin-embedded. For histology, tissue sections (5 μm) were
stained using haematoxylin and eosin or the Carstairs’method
for fibrin and platelets [18]. For immunohistochemistry, tissue
sections are stained with monoclonal antibodies and
visualised using 3,3'-diaminobenzidine (DAB) (Online
Table 1). For flow cytometry, freshly isolated whole
atherothrombotic specimens were washed and manually dis-
aggregated. A single cell homogenate is achieved using col-
lagenase, and specimens are directly stained for cell surface
antigen positivity (Online Table 2).
Phenotypic Characterisation of Endothelial Cells
For immunocytochemistry, cells are fixed in 4% paraformal-
dehyde and stained using human monoclonal antibodies and
fluorochrome-conjugated secondary antibodies (Online
Table 2). Cells are phenotyped at each passage for flow
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cytometric positivity of endothelial cell surface antigens, en-
dothelial cytoplasmic antigens, and leucocyte antigens
(Online Tables 2 and 3). For uptake of acetylated low-
density lipoprotein (LDL), confluent monolayers of endothe-
lial cells were incubated for 4 h with 1,1-dioctadecyl-
3,3,3tetramethylindocarbocyanine (DIL)-labelled acetylated
LDL. For quantification of western blot VEGF protein levels,
cells were lysed and incubated with anti-human VEGF anti-
body following manufacturer’s guidelines.
In Vitro Functional Characterisation of Endothelial
Cells
For growth kinetics, population doubling times (PDT) were
calculated according to the equation PDT = Log2 (Ch/Cs)/t,
where Ch is the cell number harvested, Cs is the cell number
seeded, and t is the time interval [12]. PDT data from the first 9
cell passages were averaged for all samples. Cumulative pop-
ulation doubling levels (CPDL) were the sum of all population
doublings. Cell adhesion was assessed by seeding cells into a
6-well collagen I-coated plate for 30 min as previously de-
scribed [19]. Plates were washed, and attachment within a
defined region of each well was quantified and expressed as
a percentage of seeded cell number. For the wound migration
assay, cells were grown to confluence and rendered quiescent
by incubation with serum-free medium for 24 h as previously
described [18]. The endothelial cell monolayer was wounded
by a linear vertical stroke across the diameter of the well using
a P1000 pipette tip. To quantify migration, the width of the
wound was visualised at the start time (0 h), and the area of
wound closure across the vertical stroke at 24 h was quantified
and expressed as a percentage of wound closure. To assess
angiogenic potential, cells were seeded into a 48-well plate
pre-coated with Matrigel™ basement membrane matrix, and
tube-like structures were quantified at 24 h. Nitrite concentra-
tions were measured by Griess Reagent (ab234044) assay
following manufacturer’s instructions. Glucose consumption
as a measurement of cell metabolism was determined by spec-
trophotometry (COBAS Mira Plus, Horiba ABX) from cell
culture media (48 h) by monitoring the production of
NAD(P) H in the specific reaction at 340 nm wavelength.
In Vivo Angiogenesis Assay
Animal experiments to evaluate in vivo neovascularisation
were performed in NOD-SCID gamma mice (NOD.Cg-
PrkdcscidIl2rgtm1WjI/SzJ) aged 10–12 weeks (n = 28), in
accordance with the British Home Office Animals
(Scientific Procedures) Act 1986. Mice were anaesthetised
intraperitoneally with Domitor containing medetomidine and
vetalar containing ketamine; both were administered at 0.1 ml
per 10 g body weight. Upon sedation, an analgesic, vetergesic
containing buprenorphine was administered subcutaneously
at 0.1 mg per kg body weight. Sterile sponges embedded with
growth factor reduced (GFR)-Matrigel™ (vehicle control)
and GFR-Matrigel™ with endothelial cells (CEO, EOC and
HUVECs) were subcutaneously implanted for 21 days [20]
after which mice were sacrificed by cervical dislocation.
Murine sponges were formalin fixed and 4 μm sections
stained with haematoxylin and eosin. Angiogenesis was
assessed using the Chalkley count method [13, 20, 21]. Host
vessels with human cells were identified using human-specific
monoclonal antibodies to endothelial cell antigens as previ-
ously described [19], and the percentage of human-specific
vessels were quantified.
Statistical Analysis
Data are shown as mean ± standard deviation. Independent
samples were analysed using the unpaired Student’s t test.
More than two groups were compared using repeated measure
or one-way analysis of variance (ANOVA) with Bonferroni
post-tests where appropriate. Categorical data were compared
using the chi-squared with Fisher’s exact test. Paired Student’s
t tests were used to compare Chalkley counts between vehicle
control- and cell-infiltrated sponges. Statistical significance
was assumed if a null hypothesis could be rejected at P ≤ 0.05.
Results
Coronary atherothrombotic specimens (n = 49) are collected
from consecutive patients with acute myocardial infarction
with specimens fixed for histology (n = 8), flow cytometry
(n = 4), or manually disaggregated for cell culture (n = 37)
(Online Fig. 1). Patients are 62 ± 12 years old (76%male) with
typical risk factors for acute coronary syndrome (Online
Table 4).
Atherothrombotic Specimens
Histological examination of atherothrombotic specimens
identifies platelets, erythrocytes, leucocytes, and fibrin with
atherosclerotic plaque containing cholesterol clefts (Fig. 1a–
e). Clusters of CD146+ cells are visualised (Fig. 1f), but no
microvessels are found. Flow cytometry analysis identified
CD146+and CD31+endothelial cells in disaggregated
atherothrombotic specimens (CD45-CD42a-CD146+ = 0.18
± 0.36% and CD45-CD42a-CD31+ = 0.11 ± 0.12% of viable
cells) (n = 4) (Online Fig. 2).
Isolation and Characterisation of Coronary
Endothelial Outgrowth Cells
Outgrowth from atherothrombotic specimens is obtained from
27/37 (73%) specimens (Online Table 5). Outgrowth was
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isolated more frequently in atherothrombotic specimens from
the right coronary artery (21/23, 91%) than the left anterior
descending artery (4/12, 33%). Colonies emerged after 2–15
days in culture forming a median of 2 colonies per specimen
(interquartile range of 6 colonies) (Fig. 2a and b). Cells are
first passaged after 21 days (range 15–28 days) and continued
to proliferate to form a confluent monolayer (Fig. 2c) with 21/
27(78%) cell lines proliferating for multiple passages (range
6–17).
Outgrowth cells had typical endothelial cell morphology
with a centrally located circular nucleus. Cells stained for
vWF and had uniform cell surface CD31 expression (Fig.
2d–l). Cells took up fluorescent-labelled acetylated-LDL
(Fig. 2j, k) stained positive for Ulex europaeus lectin (Fig.
2l, m) and formed tube-like structures on a MatrigelTM mem-
brane matrix (Fig. 2n, o) and were defined as coronary endo-
thelial outgrowth (CEO) cells. These cells were strongly pos-
itive for endothelial cell surface and cytoplasmic antigens:
CD146 (90%), CD31 (87,1%), CD105 (93,4%), intracellular
adhesionmolecule-1(ICAM-1) (81,8%), vWF (99,9%), UEA-
1 (94%), and endothelial nitric oxide synthase (eNOS)
(93,4%). A proportion of CEO cells were positive for CD34
(63,5%), CD309 (kinase domain receptor, KDR) (76,8%), and
CD133 (33,5%). Whilst the majority of endothelial antigens
was unchanged during culture, CD34 and CD133 positivity
diminished (P < 0.01) and CD105 increased (P < 0.01).
Positivity of the non-endothelial surface antigen CD45 re-
mains low (< 3%), and cells are negative for αSMA (Online
Table 6, Fig. 2p, and Online Fig. 3).
Phenotypic and Functional Comparison of Endothelial
Cells
Antigen Expression
CEO cells had a similar phenotype to control endothelial cells
(EOCs, HCAECs, and HUVECs) during early passage (1-4),
although CEO cells had lower CD45 positivity compared with
EOCs (P < 0.01; Online Table 7). At later passage (9-12),
CEO cells presented lower positivity of CD34 and higher
levels of CD309 and CD133 in comparison with HCAECs




Fig. 1 Coronary atherothrombotic specimens from patients undergoing
treatment for ST-segment elevation myocardial infarction. The border
zone between cholesterol cleft rich atheroma and thrombus is evident
(arrows) with Carstairs staining rendering erythrocytes, yellow, and
fibrin, pink (a). Atherothrombotic specimens were composed of platelets
(blue) (b), erythrocytes (c), leucocytes (d), cholesterol clefts (e), and
CD146+ endothelial cells (f) encased in fibrin. Scale bars 50 μm
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Growth Kinetics and Glucose Consumption
Proliferative activity is lower in CEO cells (population
doubling time [PDT] = 2.5 ± 1.0 days) compared to
healthy HCAECs (PDT = 1.6 ± 0.3 days; P < 0.05) and
HUVECs (PDT = 1.2 ± 0.3 days; P < 0.01) (P = 0.017)
(Fig. 3a). CEO cells had a lower cumulative population
doubling level (23.0 ± 6.8 days) during prolonged culture
(8 passages) than HCAECs (43.1 ± 2.1 days) and
HUVECs (55.5 ± 5.3 days) (P < 0.001 and P < 0.0001,
respectively) (P < 0.0001) (Fig. 3b). Metabolic measure-
ment of percentage of glucose consumption as another
indicator of cellular activity is shown to be significantly
reduced in CEO cells compared to healthy HCAECs
(Online Fig. 4).
In Vitro Adhesion, Migration, Angiogenesis Assay,
and Nitrite Concentration
CEO cells had a similar capacity to adhere to a collagen sub-
strate (81 ± 18%) than EOCs (83 ± 19%), HCAECs (93 ± 6%),
and HUVECs (88 ± 4%) (P = 0.662) (Fig. 3c). The migratory
capacity of CEO cells across a linear wound is reduced com-
pared toHUVECs (29 ± 20% versus 85 ± 19%wound closure;
P < 0.0001), but did not differ compared to EOCs (31 ± 19%)
and HCAECs (4 ± 4%) (P = 0.008) (Fig. 3d). CEO cells
formed a similar number of tube-like structures on
MatrigelTM (20 ± 30 tubules) compared to EOC (20 ± 11
tubules), HCAECs (26 ± 6 tubules), and HUVECs (44 ± 58
tubules) (P = 0.415). Additionally, CEO cells had similar









Fig. 2 Outgrowth and characterisation of coronary endothelial outgrowth
cells from atherothrombotic specimens. Outgrowth of coronary
endothelial cells from dissected atherothrombotic specimen at 24 hours
(a), colony formation at 7 days (b), and confluent cobblestone
morphology at first passage (c). Cells stain positive for cytoplasmic
expression of granular von Willebrand factor indicative of Weibel–
Palade bodies (pink) and cell surface expression of CD31 (green) with
4',6-diamidino-2-phenylindole (DAPI) as a nuclei counterstain (blue) (d).
Uptake of fluorescent labelled Dil-acetylated-LDL (red) with DAPI as a
counterstain (e) and tube-like structure formation onMatrigelTM(f). Scale
bar 100 μm. Coronary endothelial outgrowth cells strongly express cell
surface antigens CD146, CD31, CD105, and CD54 and cytoplasmic an-
tigens von Willebrand factor (vWF) and endothelial nitric oxide synthase
(eNOS), but do not express the pan leucocyte antigen CD45. Unstained
(grey) and stained cells (black) (g)
Cardiovasc Drugs Ther
western blot and similar nitrite concentration levels than con-
trol HUVECs and HCAECs (Online Fig. 4).
In Vivo Angiogenesis Assay
Implantation of CEO cells into a subcutaneous sponge did not
alter vessel density compared to vehicle control (Chalkley
count 7 ± 1 versus 6 ± 1, P = 0.207) (Fig. 4a), nor did CEO
cells incorporate into vascular structures (Fig. 5a–c and j).
HUVECs, but not EOCs, increased vessel density compared
to vehicle control (11 ± 1 versus 7 ± 1, P = 0.030 and 7 ± 1
versus 7 ± 2 P = 0.365 respectively; Fig. 4b and c), and both
are found to incorporate into murine vessels (HUVECs: 25
±19%; EOCs: 25 ± 19% vessels with human cells) (P =
0.019) (Fig. 5d–i and j).
Discussion
Endothelial dysfunction is key to the pathogenesis of acute
coronary syndrome. However, our understanding of the role
of the coronary endothelium is based largely on the study of
endothelial cells derived from more readily available vascular
beds. Here, we report the first successful expansion of coro-
nary endothelial cells from coronary atherothrombotic speci-
mens obtained from patients undergoing treatment for acute
myocardial infarction. We systematically compared the phe-
notype and function of these cells with endothelial outgrowth
progenitor cells isolated from the peripheral circulation and
with mature human coronary artery cells and umbilical vein
endothelial cells. This study demonstrated that CEO cells are
phenotypically similar to control mature endothelial cells but
have marked diseased-specific dysfunctional characteristics
both in vitro and in vivo. Our results indicate that
atherothrombotic specimens are a viable and important
sources of endothelial cells to understand the role and the
insights of endothelial dysfunction in the pathogenesis of cor-
onary artery disease.
Studied atherothrombotic specimens were heterogeneous
and rich in erythrocytes, leucocytes, fibrin, and cholesterol
clefts as previously reported [22, 23]. We found isolated en-
dothelial cells and buried fibrous caps, although the number of
CD146+ and CD31+cells in digested specimens was low (<
1%) which is consistent with previous observations [24]. We
derived outgrowth from manually dissected whole
atherothrombotic specimens without cell selection based on
endothelial cell surface markers, and therefore, we carefully
assessed our outgrowth for endothelial phenotypic markers
and functional characteristics. CEO cells were positive for
variety of mature endothelial cell markers, incorporated acet-
ylated LDL, and formed tube-like structures on MatrigelTM
confirming an endothelial cell identity. Furthermore, the
Fig. 3 Proliferation, adhesion, and wound migration of coronary
endothelial outgrowth cells in vitro. Coronary endothelial outgrowth
(CEO) cells had a higher population doubling time (PDT) during the first
9 passage in comparison to human coronary artery endothelial cells
(HCAECs) and human umbilical vein endothelial cells (HUVECs)
(one-way analysis of variance P = 0.017; Bonferroni post-test *P <
0.05 and **P < 0.01, respectively. n = 3–9) (a) and a lower cumulative
population doubling level (CPDL) when maintained long term in culture
(P < 0.0001; Bonferroni post-test ***P < 0.001 and ****P < 0.0001,
respectively. n = 3–9) (b). CEO cells had a similar capacity to adhere to a
collagen substrate in vitro (P = 0.662. n = 3–10) (c), but following the
infliction of a linear wound in the endothelial cell monolayer, CEO cells
had a reduced capacity to migrate in vitro in comparison to HUVECs (P =
0.008; Bonferroni post-test ****P < 0.0001. n = 3–7) (d)
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proportion of outgrowth cells that were positive with the pan-
leucocyte marker CD45 was low (< 4%) suggesting minimal
contamination from inflammatory cells.
To our knowledge, we report the first attempt to isolate, ex-
pand, and characterise endothelial cells from atherothrombotic
specimens. One previous study obtained endothelial cells from
coronary guidewires using CD146 immunomagnetic beads [25].
However, they were unable to expand these cells in vitro, and
limited characterisation was performed. Although the authors
speculate that they were unable to expand cells due to endothelial
dysfunction, it is as likely that expansion failed due to the very
low yield of cells from the coronary guidewire. Other methods
involving wire biopsies of the superficial veins and arteries of the
forearm have been more successful in the isolation and expan-
sion of endothelial cells in culture [11, 26, 27], but these beds are
largely protected from atherosclerosis. As such, we suggest that
CEO cells obtained from atherothrombotic specimens, the most
representative and relevant endothelial cells to study the patho-
genesis of atherosclerosis.
Compared with commercially available control endothelial
cells from human cadaveric coronary arteries and human um-
bilical veins, CEO cells had lower rates of proliferation and
glucose consumption. Furthermore, CEO cells had a reduced
migratory and angiogenic capacity compared with HUVECs
and were unable to incorporate into new vascular beds in our
experimental model of angiogenesis. Given other aspects of
endothelial function, such as vasodilatation and fibrinolysis,
are impaired in patients with coronary artery disease [5, 28],
this result is not unexpected. As CEO cells were isolated from
ruptured plaques during an acute myocardial infarction, it is
likely that they have experienced oxidative stress and ische-
mic injury affecting their function. As these differences
persisted in CEOs following multiple passages and expansion
in optimal culture conditions, our results indicate there is an
inherent difference in the function of endothelial cells derived
from coronary atherosclerotic plaques.
Further work is required to understand the mechanistic
pathways that influence the function of coronary endothelial
outgrowth cells, including the role of clinical features, cellular
metabolism, inflammation, and shear stress. This research
could help identify new targets for drug discovery beyond
established pathways such as nitric oxide biosynthesis, fibri-
nolysis, and platelet aggregation, which could link coronary
endothelial dysfunction to acute atherothrombosis.
Limitations
It was not possible to obtain coronary artery endothelial cells
from age-matched controls given the invasive nature of the
thrombectomy procedure, and therefore, we cannot definitively
conclude that functional differences of CEO cells are a cause or
consequence of atherosclerosis, coronary heart disease, or age.
Furthermore, whilst all cells were cultured in identical conditions
a b c
d e
Fig. 4 Angiogenic potential of coronary endothelial outgrowth cells
in vivo. Sponges embedded with growth factor reduced (GFR)-
MatrigelTM (vehicle control) and GFR-MatrigelTM with coronary
endothelial outgrowth (CEO) cells (a), late endothelial outgrowth cells
(EOCs) (b), or human umbilical vein endothelial cells (HUVECs) (c)
were subcutaneously implanted into male NOD-SCID gamma mice.
CEO cells and EOCs did not increase blood vessel number compared to
vehicle controls (paired t test P = 0.207 and P = 0.365, respectively. n =
12), whereas HUVECs did increase vessel number (paired t test P =
0.030. n = 4). Light microscopy of haematoxylin/eosin stained sponge
4-μm sections from CEO impregnated sponge (d) and HUVEC impreg-
nated sponge (e) (black arrows identify vessels)
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and evaluated as the same passage, we cannot completely ex-
clude that the method used to isolated cells could account for
some of the differences observed. However, we included multi-
ple controls including endothelial outgrowth cells from patients
with coronary heart disease and coronary artery endothelial cells
isolated from cadaveric hearts.
Summary
In conclusion, this study reports a novel method to isolate and
expand coronary endothelial cells from thrombectomy speci-
mens, harvested during primary percutaneous coronary interven-
tion for acute ST-segment elevation myocardial infarction. Our
Fig. 5 Coronary endothelial outgrowth cells do not incorporate into
murine vessels in vivo. Immunohistochemistry of subcutaneously
implanted sponges embedded with CEO cells (a–c), EOCs (d–f), and
HUVECs (g–i). Sections were stained with antibodies cross-reactive to
both mouse and human antigens (red) or specific to human antigens
(green) using 4',6-diamidino-2-phenylindole (DAPI) as a counterstain.
Auto-fluorescent erythrocytes are presence in vessel lumen demonstrates
the vessels were contiguous with the host circulation. Scale bars 50 μm.
In contrast to late endothelial outgrowth cells (EOCs) and human umbil-
ical vein endothelial cells (HUVECs), coronary endothelial outgrowth
(CEO) cells did not incorporate into murine vessel (j) (one-way analysis
of variance P = 0.019; Bonferroni post-test *P < 0.05 for CEO cells
versus HUVECs. n = 4–10)
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results show that these cells are dysfunctional with an impaired
capacity to proliferate, migrate, and contribute to angiogenesis,
compared to healthy endothelial cells isolated from different vas-
cular beds. This novel approach could have an impact on clinical
practice as they may be used as tools to identify and test novel
therapeutic targets and molecular pathways to correct endothelial
function and prevent acute coronary syndrome.
Non-standard Abbreviations and Acronyms ANOVA, Analysis of vari-
ance; APC, Allophycocyanin; CEO, Coronary endothelial outgrowth;
CPDL, Cumulative population doubling level; DAB, 3,3’-
Diaminobenzidine; DAPI, 4',6-Diamidino-2-phenylindole; DIL, 1,1′-
Dioc tadecy l -3 ,3 ,3 ′ t e t ramethy l indocarbocyan ine ; EDTA,
Ethylenediaminetetraacetic acid; eNOS, Endothelial nitric oxide syn-
thase; EOCs, Endothelial outgrowth cells; FBS, Foetal bovine serum;
FITC , Fluorescein isothiocyanate; GFR, Growth factor reduced;
HCAECs, Human coronary artery endothelial cells; HUVECs, Human
umbilical vein endothelial cells; KDR, Kinase domain receptor; LDL,
Low-density lipoprotein; NGS, Normal goat serum; PBS, Phosphate
buffered saline; PCI , Percutaneous coronary intervention; PDT,
Population doubling time; PE, Phycoerythrin; PFA, Paraformaldehyde;
STEMI, ST-segment elevation myocardial infarction; vWF, von
Willebrand factor
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